Ensoylu M.Deliormanlı A.M.Atmaca H.2024-07-222024-07-22202100222461http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13163In the study, tungsten disulfide (WS2) nanoparticle-containing polymer-coated bioactive glass composite scaffolds were prepared for bone tissue engineering applications. Poly-ε-caprolactone (PCL) and poly(D,L-lactide-co-glycolide) (PLGA) were applied on the surface of the bioactive glass scaffolds fabricated by the polymer foam replication method. Results revealed that the presence of WS2 nanoparticles (0.1 to 2 wt%) embedded in polymer matrix improved the compression strength of the prepared scaffolds and their in vitro bioactivity in simulated body fluid. Composite scaffolds did not demonstrate a cytotoxic effect on pre-osteoblastic MC3T3-E1 cells after incubation for 72 h. SEM analysis showed that cells attached to the surface of the scaffolds and spread through the interconnected porous network. Gentamicin-loaded scaffolds demonstrated a controlled drug release behavior depending on the type of polymer applied on the coating layer. The presence of WS2 nanoparticles enhanced the drug release behavior of the scaffolds. It was concluded that bioactive glass-based composites fabricated in the study have the potential to be used for bone tissue engineering purposes. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.EnglishBody fluidsControlled drug deliveryNanoparticlesPlastic coatingsScaffoldsScaffolds (biology)Sulfur compoundsTargeted drug deliveryTissueTungsten compoundsBone tissue engineeringComposite scaffoldsDrug-release behaviourGlass compositesGlass scaffoldsGlycolideL-lactidePoly(ε caprolactone)Polymer foamsTissue engineering applicationsBioactive glassArticle10.1007/s10853-021-06494-w